Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors
€5 million convertible bonds issued to European investors,
European investors have also provided written indication of strong interest for the potential of additional €25 million in similar convertible bonds, depending on future market conditions
PARIS, FRANCE / ACCESSWIRE / February 4, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the
Company ), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY platform, today announced a financing of €11 million through the combination of a €6 million capital raise subscribed by two existing shareholders by way of issuance of new ordinary shares (the
Oxford, U.K. 5 February 2021 : Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division. Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company s global product for value-based care and previously its global product proposition in the women s health space. Prior to that, Hina founded the UK s first virtual care platform for women s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte
T: +44 20 3709 5700
hyloris@consilium-comms.com
About Hyloris Pharmaceuticals SA
Based in Liège, Belgium, Hyloris is an innovative specialty pharmaceutical company focused on adding value to the healthcare system by reformulating well-known pharmaceuticals. Hyloris develops proprietary products it believes offer significant advantages compared to currently available alternatives, with the aim to address the underserved medical needs of patients, hospitals, physicians, payors and other stakeholders in the healthcare system. Hyloris currently has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, commercialised through its partner AltaThera, and Maxigesic® IV, a non-opioid analgesic product for the treatment of pain, developed with the Company s partner, AFT Pharmaceuticals. Additionally, Hyloris has 12 product candidates in various stages of development across the Company s wider portfolio with a focus on intravenous cardiovascular dru
Achilles Therapeutics Announces Independent Data and Safety Monitoring Committee Review with a Positive Recommendation to Continue with Current Study Design of the Phase I/IIa CHIRON and THETIS Trials
Phase I/IIa CHIRON and THETIS Trials
London, UK 5 February 2021 - Achilles Therapeutics ( Achilles or the Company ), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an Independent Data and Safety Monitoring Committee (IDSMC) has completed its first review of the ongoing, first-in-human Phase I/IIa CHIRON and THETIS trials and has recommended that both clinical trials continue as planned. In this review of the first six patients dosed with the Company s Clonal Neoantigen Targeting T cell therapy (cNeTs), the overall tolerability profile was generally similar to that of standard tumor-infiltrating lymphocyte (TIL) products that have not been enriched for cNeT reactivities, with the lymphodepletion regimen acc